Lumanity and the Parker Institute for Cancer Immunotherapy (PICI) have announced an alliance to accelerate the development and delivery of new cancer immunotherapies.
The partnership brings together PICI’s translational research expertise and network of collaborators with Lumanity’s commercial and development strategy capabilities.
The agreement will see Lumanity provide targeted support to selected PICI-affiliated programmes advancing toward clinical development, company formation or commercialisation. Areas of collaboration may include indication prioritisation, evidence generation and market access planning.
The alliance is designed to improve development efficiency and support earlier strategic decision-making in a space where scientific advances are often slowed by challenging regulatory, access and reimbursement pathways.
Tarak Mody, Chief Business Officer at PICI, commented: “Together, we’re strengthening the infrastructure that helps therapies reach patients with a clearer value proposition.”
Jeff Bockman, Head of Lumanity’s Oncology Center of Excellence, added: “Our goal is to guide promising science through the decisions that determine whether it ultimately reaches patients.”
The collaboration reflects a shared focus on aligning scientific discovery with practical delivery. Patient recruitment, regulatory scrutiny and real-world value assessment continue to shape the trajectory of immunotherapy development, making partnerships such as these increasingly important.
